# 總部位於班加羅爾的細胞與基因療法新創公司 Immuneel Therapeutics 在 B 輪融資中籌得逾 100 億盧比。

*biotech · news · 2026-06-08 · Moneycontrol*

## Key points

- Immuneel Therapeutics 在 B 輪融資中籌得逾 100 億盧比，新增 Singularity AMC 與 Rainmatter 為投資者。
- 資金將用於擴展 GMP 製造、Qartemi 商業化及進軍亞太與中東市場。
- Qartemi 是印度首款獲批用於非霍奇金淋巴瘤的 CAR-T 療法，現已商業上市。
- Immuneel 正在澳洲與東南亞啟動細胞療法臨床共同開發合作。
- 公司計劃開發新一代細胞與基因療法，目標降低治療成本與複雜度。

Bengaluru-based cell and gene therapy startup Immuneel Therapeutics has raised over Rs 100 crore in a Series B funding round, bringing on board new investors including Singularity AMC, Rainmatter by Zerodha, and several high-net-worth individuals (HNIs), the company said on June 8. The round also saw participation from existing investors including Kiran Mazumdar-Shaw, Eight Roads Ventures, and F-Prime Capital. The fresh capital will be deployed towards expanding Immuneel's Good Manufacturing Practice (GMP) manufacturing capacity, advancing its next-generation cell and gene therapy pipeline, supporting the commercialisation of its CAR-T therapy product Qartemi, and accelerating the company's international expansion plans across the Asia-Pacific and Middle East regions. The fundraise comes as Immuneel looks to build on the commercial launch of Qartemi, India's first approved CAR-T therapy for Non-Hodgkin Lymphoma, while broadening its presence in global markets and advancing new therapies for blood cancers. "This company was founded with the belief that advanced cell therapies should not remain confined to a small segment of patients or a handful of geographies. This fundraise strengthens our ability to build a globally competitive CAR-T platform from India combining deep science, scalable manufacturing and significantly improved affordability," said Kiran Mazumdar-Shaw, founder of Immuneel Therapeutics. Founded as a clinical-stage biotechnology company, Immuneel operates what it describes as India's first international-standard CAR-T platform. The company said it is expanding into high-growth markets and progressing clinical co-development partnerships in Australia and Southeast Asia. Chief Executive Officer Amit Mookim said the company is entering its next phase of growth following Qartemi's launch. "Qartemi's commercialisation proved we can deliver world-class CAR-T outcomes at a fraction of Western costs. This Series B financing accelerates what comes next: a bold international expansion and a next-generation pipeline that will redefine how cell therapies reach patients globally," Mookim said. According to the company, the funding will also support research and development efforts aimed at building a broader portfolio of novel cell and gene therapies. For Singularity AMC, the investment represents a bet on the growing role of advanced oncology treatments in India and other emerging markets. "Immuneel is changing that. What excites us most is the breadth of their pipeline: from expanding into new blood cancer indications to next-generation modalities that could dramatically reduce the cost and complexity of treatment," said Aravind Viswanathan, Senior Operating Partner at Singularity AMC. Rainmatter founder Nithin Kamath said the investment aligns with the firm's focus on supporting healthcare innovations with long-term societal impact. "Cancer remains one of the most devastating diseases of our time and the most advanced treatments have been out of reach for most Indians. We're excited to support Immuneel, who are bringing cell and gene therapies, including CAR-T, to Indian patients with a focus on outcomes and accessibility," Kamath said. Immuneel was founded by Mazumdar-Shaw and has positioned itself as a platform focused on making advanced cell and gene therapies more affordable and accessible. The company is currently advancing a next-generation pipeline alongside scaling manufacturing and commercial operations following the launch of Qartemi.

**Companies:** Immuneel Therapeutics
**Countries:** India, Australia

[Read the full story on Moneycontrol](https://www.moneycontrol.com/news/business/immuneel-raises-over-rs-100-crore-in-funding-led-by-singularity-amc-rainmatter-13943734.html)

---

Canonical: https://newsio.io/zh-TW/n/85b9cdf6-953c-496a-a15d-074d08543615/immuneel-therapeutics-b-100-singularity-amczerodha-rainmatter
Summarized by Newsio from Moneycontrol. https://newsio.io/how-it-works